fbpx

Clinical Studies

If you are interested in learning more about our ongoing clinical studies, please contact us at ClinicalStudies@atarabio.com.
For a comprehensive list of studies, please check clinicaltrials.gov.

Phase Trial Number Trial Description
Atara tab-cel® (tabelecleucel; formerly called Atara ATA129) 3 NCT03392142 Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With EBV+ PTLD After Failure of Rituximab (MATCH)
3 NCT03394365 Tabelecleucel for Solid Organ Transplant Subjects With EBV+ PTLD After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)
1/2 NCT03769467 Tabelecleucel in Combination With Pembrolizumab in Subjects With EBV+ Nasopharyngeal Carcinoma
1/2 NCT00002663 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Atara ATA188 1 NCT03283826 Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis
Atara ATA230 2 NCT02136797 Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
2 NCT01646645 Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation